神经退行性药物市场：按药物类别、适应症、分销渠道：2021 |
您所在的位置：网站首页 › 神经退行性疾病治疗药物 › 神经退行性药物市场：按药物类别、适应症、分销渠道：2021 |
|
Product Code: A13213 The neurodegenerative drugs market valued for $36,277.20 million in 2021 and is estimated to reach $74,809.38 million by 2031, exhibiting a CAGR of 7.5% from 2022 to 2031. Neurodegenerative diseases refer to a group of disorders that primarily affect the neurons (nerve cells) in the brain and spinal cord, leading to their gradual degeneration. These diseases are usually progressive and chronic, and their symptoms worsen over time. Examples of neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). These conditions have a significant impact on a person's cognitive, motor, & sensory functions, and can ultimately lead to disability and death. Drugs used to treat neurodegenerative diseases are medications that are designed to slow down the progression of the disease and/or relieve symptoms. The specific drugs used will depend on the type of neurodegenerative disease being treated. For example, drugs used to treat Alzheimer's disease include cholinesterase inhibitors and memantine, while drugs used to treat Parkinson's disease include levodopa, dopamine agonists, and MAO-B inhibitors. The major factor that drives the growth of the global neurodegenerative drugs market is rise in demand for advanced drug types for controlling symptoms associated with neurodegenerative diseases. In addition, a strong pipeline for neurodegenerative disease is a key trend in the market, which is expected to fuel the growth of the market. Significant surge in patient population has led to increase in demand for drugs. However, complications associated with drug development process and side effects of drugs are expected to hamper the market growth. On the other hand, high growth potential in untapped emerging countries, increase in pipeline products such as BAF312 & Orelabrutinib for treating multiple sclerosis disease, and continuous drug approval of neurodegenerative diseases are anticipated to provide lucrative opportunities to the market players. For instance, in January 2020, Novartis AG announced that the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. The neurodegenerative drugs market is segmented into drug class, indication, distribution channel, and region. By drug class, the market is categorized into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators, and others. By indication, the market is segregated into Parkinson's disease, Alzheimer's disease, multiple sclerosis, and others. By distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global neurodegenerative drugs market are: AbbVie Inc., Biogen, F. Hoffmann-La Roche Ltd., Novartis AG, Orion Corporation, Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and UCB S.A. Key players operating in the market have adopted product approval, acquisition, collaboration, and agreement as their key strategies to expand their corporate training market share. Key Benefits For Stakeholders This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neurodegenerative drugs market analysis from 2021 to 2031 to identify the prevailing neurodegenerative drugs market opportunities. The market research is offered along with information related to key drivers, restraints, and opportunities. Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. In-depth analysis of the neurodegenerative drugs market segmentation assists to determine the prevailing market opportunities. Major countries in each region are mapped according to their revenue contribution to the global market. Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. The report includes the analysis of the regional as well as global neurodegenerative drugs market trends, key players, market segments, application areas, and market growth strategies. Key Market Segments By Drug Class Dopamine agonist Decarboxylase inhibitors Cholinesterase Inhibitors Immunomodulators Others By Indication Parkinson's Disease Alzheimer's Disease Multiple Sclerosis Others By Distribution Channel Hospital Pharmacies Online Providers Drug Stores and Retail Pharmacies By Region North America U.S. Canada Mexico Europe Germany France UK Italy Spain Rest of Europe Asia-Pacific Japan China Australia India South Korea Rest of Asia-Pacific LAMEA Brazil Saudi Arabia South Africa Rest of LAMEA Key Market Players: F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Orion Corporation Biogen Sanofi Viatris Inc. Novartis AG UCB S.A. AbbVie Inc. TABLE OF CONTENTS CHAPTER 1: INTRODUCTION 1.1. Report description 1.2. Key market segments 1.3. Key benefits to the stakeholders 1.4. Research Methodology 1.4.1. Primary research 1.4.2. Secondary research 1.4.3. Analyst tools and models CHAPTER 2: EXECUTIVE SUMMARY 2.1. CXO Perspective CHAPTER 3: MARKET OVERVIEW 3.1. Market definition and scope 3.2. Key findings 3.2.1. Top impacting factors 3.2.2. Top investment pockets 3.3. Porter's five forces analysis 3.3.1. Bargaining power of suppliers 3.3.2. Bargaining power of buyers 3.3.3. Threat of substitutes 3.3.4. Threat of new entrants 3.3.5. Intensity of rivalry 3.4. Market dynamics 3.4.1. Drivers 3.4.1.1. Increase in prevalence of neurodegenerative diseases 3.4.1.2. Initiatives by government and non-government organizations 3.4.1.3. Expected launch of new drugs during the forecast period 3.4.2. Restraints 3.4.2.1. Complications associated with drug development 3.4.3. Opportunities 3.4.3.1. Increase in R&D activities 3.5. COVID-19 Impact Analysis on the market CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS 4.1. Overview 4.1.1. Market size and forecast 4.2. Dopamine agonist 4.2.1. Key market trends, growth factors and opportunities 4.2.2. Market size and forecast, by region 4.2.3. Market share analysis by country 4.3. Decarboxylase inhibitors 4.3.1. Key market trends, growth factors and opportunities 4.3.2. Market size and forecast, by region 4.3.3. Market share analysis by country 4.4. Cholinesterase Inhibitors 4.4.1. Key market trends, growth factors and opportunities 4.4.2. Market size and forecast, by region 4.4.3. Market share analysis by country 4.5. Immunomodulators 4.5.1. Key market trends, growth factors and opportunities 4.5.2. Market size and forecast, by region 4.5.3. Market share analysis by country 4.6. Others 4.6.1. Key market trends, growth factors and opportunities 4.6.2. Market size and forecast, by region 4.6.3. Market share analysis by country CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION 5.1. Overview 5.1.1. Market size and forecast 5.2. Parkinson's Disease 5.2.1. Key market trends, growth factors and opportunities 5.2.2. Market size and forecast, by region 5.2.3. Market share analysis by country 5.3. Alzheimer's Disease 5.3.1. Key market trends, growth factors and opportunities 5.3.2. Market size and forecast, by region 5.3.3. Market share analysis by country 5.4. Multiple Sclerosis 5.4.1. Key market trends, growth factors and opportunities 5.4.2. Market size and forecast, by region 5.4.3. Market share analysis by country 5.5. Others 5.5.1. Key market trends, growth factors and opportunities 5.5.2. Market size and forecast, by region 5.5.3. Market share analysis by country CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL 6.1. Overview 6.1.1. Market size and forecast 6.2. Hospital Pharmacies 6.2.1. Key market trends, growth factors and opportunities 6.2.2. Market size and forecast, by region 6.2.3. Market share analysis by country 6.3. Online Providers 6.3.1. Key market trends, growth factors and opportunities 6.3.2. Market size and forecast, by region 6.3.3. Market share analysis by country 6.4. Drug Stores and Retail Pharmacies 6.4.1. Key market trends, growth factors and opportunities 6.4.2. Market size and forecast, by region 6.4.3. Market share analysis by country CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION 7.1. Overview 7.1.1. Market size and forecast By Region 7.2. North America 7.2.1. Key trends and opportunities 7.2.2. Market size and forecast, by Drug Class 7.2.3. Market size and forecast, by Indication 7.2.4. Market size and forecast, by Distribution Channel 7.2.5. Market size and forecast, by country 7.2.5.1. U.S. 7.2.5.1.1. Key market trends, growth factors and opportunities 7.2.5.1.2. Market size and forecast, by Drug Class 7.2.5.1.3. Market size and forecast, by Indication 7.2.5.1.4. Market size and forecast, by Distribution Channel 7.2.5.2. Canada 7.2.5.2.1. Key market trends, growth factors and opportunities 7.2.5.2.2. Market size and forecast, by Drug Class 7.2.5.2.3. Market size and forecast, by Indication 7.2.5.2.4. Market size and forecast, by Distribution Channel 7.2.5.3. Mexico 7.2.5.3.1. Key market trends, growth factors and opportunities 7.2.5.3.2. Market size and forecast, by Drug Class 7.2.5.3.3. Market size and forecast, by Indication 7.2.5.3.4. Market size and forecast, by Distribution Channel 7.3. Europe 7.3.1. Key trends and opportunities 7.3.2. Market size and forecast, by Drug Class 7.3.3. Market size and forecast, by Indication 7.3.4. Market size and forecast, by Distribution Channel 7.3.5. Market size and forecast, by country 7.3.5.1. Germany 7.3.5.1.1. Key market trends, growth factors and opportunities 7.3.5.1.2. Market size and forecast, by Drug Class 7.3.5.1.3. Market size and forecast, by Indication 7.3.5.1.4. Market size and forecast, by Distribution Channel 7.3.5.2. France 7.3.5.2.1. Key market trends, growth factors and opportunities 7.3.5.2.2. Market size and forecast, by Drug Class 7.3.5.2.3. Market size and forecast, by Indication 7.3.5.2.4. Market size and forecast, by Distribution Channel 7.3.5.3. UK 7.3.5.3.1. Key market trends, growth factors and opportunities 7.3.5.3.2. Market size and forecast, by Drug Class 7.3.5.3.3. Market size and forecast, by Indication 7.3.5.3.4. Market size and forecast, by Distribution Channel 7.3.5.4. Italy 7.3.5.4.1. Key market trends, growth factors and opportunities 7.3.5.4.2. Market size and forecast, by Drug Class 7.3.5.4.3. Market size and forecast, by Indication 7.3.5.4.4. Market size and forecast, by Distribution Channel 7.3.5.5. Spain 7.3.5.5.1. Key market trends, growth factors and opportunities 7.3.5.5.2. Market size and forecast, by Drug Class 7.3.5.5.3. Market size and forecast, by Indication 7.3.5.5.4. Market size and forecast, by Distribution Channel 7.3.5.6. Rest of Europe 7.3.5.6.1. Key market trends, growth factors and opportunities 7.3.5.6.2. Market size and forecast, by Drug Class 7.3.5.6.3. Market size and forecast, by Indication 7.3.5.6.4. Market size and forecast, by Distribution Channel 7.4. Asia-Pacific 7.4.1. Key trends and opportunities 7.4.2. Market size and forecast, by Drug Class 7.4.3. Market size and forecast, by Indication 7.4.4. Market size and forecast, by Distribution Channel 7.4.5. Market size and forecast, by country 7.4.5.1. Japan 7.4.5.1.1. Key market trends, growth factors and opportunities 7.4.5.1.2. Market size and forecast, by Drug Class 7.4.5.1.3. Market size and forecast, by Indication 7.4.5.1.4. Market size and forecast, by Distribution Channel 7.4.5.2. China 7.4.5.2.1. Key market trends, growth factors and opportunities 7.4.5.2.2. Market size and forecast, by Drug Class 7.4.5.2.3. Market size and forecast, by Indication 7.4.5.2.4. Market size and forecast, by Distribution Channel 7.4.5.3. Australia 7.4.5.3.1. Key market trends, growth factors and opportunities 7.4.5.3.2. Market size and forecast, by Drug Class 7.4.5.3.3. Market size and forecast, by Indication 7.4.5.3.4. Market size and forecast, by Distribution Channel 7.4.5.4. India 7.4.5.4.1. Key market trends, growth factors and opportunities 7.4.5.4.2. Market size and forecast, by Drug Class 7.4.5.4.3. Market size and forecast, by Indication 7.4.5.4.4. Market size and forecast, by Distribution Channel 7.4.5.5. South Korea 7.4.5.5.1. Key market trends, growth factors and opportunities 7.4.5.5.2. Market size and forecast, by Drug Class 7.4.5.5.3. Market size and forecast, by Indication 7.4.5.5.4. Market size and forecast, by Distribution Channel 7.4.5.6. Rest of Asia-Pacific 7.4.5.6.1. Key market trends, growth factors and opportunities 7.4.5.6.2. Market size and forecast, by Drug Class 7.4.5.6.3. Market size and forecast, by Indication 7.4.5.6.4. Market size and forecast, by Distribution Channel 7.5. LAMEA 7.5.1. Key trends and opportunities 7.5.2. Market size and forecast, by Drug Class 7.5.3. Market size and forecast, by Indication 7.5.4. Market size and forecast, by Distribution Channel 7.5.5. Market size and forecast, by country 7.5.5.1. Brazil 7.5.5.1.1. Key market trends, growth factors and opportunities 7.5.5.1.2. Market size and forecast, by Drug Class 7.5.5.1.3. Market size and forecast, by Indication 7.5.5.1.4. Market size and forecast, by Distribution Channel 7.5.5.2. Saudi Arabia 7.5.5.2.1. Key market trends, growth factors and opportunities 7.5.5.2.2. Market size and forecast, by Drug Class 7.5.5.2.3. Market size and forecast, by Indication 7.5.5.2.4. Market size and forecast, by Distribution Channel 7.5.5.3. South Africa 7.5.5.3.1. Key market trends, growth factors and opportunities 7.5.5.3.2. Market size and forecast, by Drug Class 7.5.5.3.3. Market size and forecast, by Indication 7.5.5.3.4. Market size and forecast, by Distribution Channel 7.5.5.4. Rest of LAMEA 7.5.5.4.1. Key market trends, growth factors and opportunities 7.5.5.4.2. Market size and forecast, by Drug Class 7.5.5.4.3. Market size and forecast, by Indication 7.5.5.4.4. Market size and forecast, by Distribution Channel CHAPTER 8: COMPETITIVE LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Top player positioning, 2021 CHAPTER 9: COMPANY PROFILES 9.1. Novartis AG 9.1.1. Company overview 9.1.2. Key Executives 9.1.3. Company snapshot 9.1.4. Operating business segments 9.1.5. Product portfolio 9.1.6. Business performance 9.1.7. Key strategic moves and developments 9.2. AbbVie Inc. 9.2.1. Company overview 9.2.2. Key Executives 9.2.3. Company snapshot 9.2.4. Operating business segments 9.2.5. Product portfolio 9.2.6. Business performance 9.2.7. Key strategic moves and developments 9.3. F. Hoffmann-La Roche Ltd. 9.3.1. Company overview 9.3.2. Key Executives 9.3.3. Company snapshot 9.3.4. Operating business segments 9.3.5. Product portfolio 9.3.6. Business performance 9.4. Teva Pharmaceutical Industries Ltd. 9.4.1. Company overview 9.4.2. Key Executives 9.4.3. Company snapshot 9.4.4. Operating business segments 9.4.5. Product portfolio 9.4.6. Business performance 9.4.7. Key strategic moves and developments 9.5. Sanofi 9.5.1. Company overview 9.5.2. Key Executives 9.5.3. Company snapshot 9.5.4. Operating business segments 9.5.5. Product portfolio 9.5.6. Business performance 9.6. Orion Corporation 9.6.1. Company overview 9.6.2. Key Executives 9.6.3. Company snapshot 9.6.4. Operating business segments 9.6.5. Product portfolio 9.6.6. Business performance 9.7. Sun Pharmaceutical Industries Ltd. 9.7.1. Company overview 9.7.2. Key Executives 9.7.3. Company snapshot 9.7.4. Operating business segments 9.7.5. Product portfolio 9.7.6. Business performance 9.8. UCB S.A. 9.8.1. Company overview 9.8.2. Key Executives 9.8.3. Company snapshot 9.8.4. Operating business segments 9.8.5. Product portfolio 9.8.6. Business performance 9.8.7. Key strategic moves and developments 9.9. Viatris Inc. 9.9.1. Company overview 9.9.2. Key Executives 9.9.3. Company snapshot 9.9.4. Operating business segments 9.9.5. Product portfolio 9.9.6. Business performance 9.10. Biogen 9.10.1. Company overview 9.10.2. Key Executives 9.10.3. Company snapshot 9.10.4. Operating business segments 9.10.5. Product portfolio 9.10.6. Business performance 9.10.7. Key strategic moves and developments |
今日新闻 |
推荐新闻 |
| CopyRight 2018-2019 办公设备维修网 版权所有 豫ICP备15022753号-3 |